Bulevirtide

Bulevirtide is a peptide that is used as a therapeutic agent in the treatment of hepatitis D and hepatitis B. It is a first-in-class entry inhibitor that prevents the virus from entering the hepatocytes and thus inhibits viral replication.

Etymology

The name "Bulevirtide" is derived from the words "Bule" and "virtide". The exact etymology is not known, but it is believed that the name is a combination of scientific terms related to its function and structure.

Mechanism of Action

Bulevirtide works by targeting the sodium taurocholate cotransporting polypeptide (NTCP), a protein that is used by the hepatitis D and B viruses to enter hepatocytes. By binding to this protein, Bulevirtide prevents the viruses from entering the cells and thus inhibits their replication.

Clinical Use

Bulevirtide is used in the treatment of chronic hepatitis D in adults with compensated liver disease. It is administered as a subcutaneous injection once daily. The drug has been shown to significantly reduce the levels of hepatitis D virus in the blood, leading to improved liver function and reduced risk of liver-related complications.

Side Effects

The most common side effects of Bulevirtide include fatigue, headache, abdominal pain, and nausea. In rare cases, it can cause serious side effects such as severe allergic reactions and liver problems.

Related Terms

• Hepatitis D
• Hepatitis B
• Peptide
• Therapeutic agent
• Hepatocytes
• Sodium taurocholate cotransporting polypeptide
• Viral replication

Bulevirtide Resources
Latest articles Most recent articles Ongoing trials	Wikipedia